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Channel blockersThe recent outbreaks of avian ﬂu in Southeast Asia and swine ﬂu in Mexico City painfully exemplify the
ability of the inﬂuenza virus to rapidly mutate and develop resistance to modern medicines. This review
seeks to detail the molecular mechanism by which the inﬂuenza virus has obtained resistance to amino-
adamantyls, one of only two classes of drugs that combat the ﬂu. Amino-adamantyls target the viral M2 H+
channel and have become largely ineffective due to mutations in the transmembrane domain of the protein.
Herein we describe these resistance rendering mutations and the compounded effects they have upon the
protein's function and resulting virus viability.strahan), arkin@huji.ac.il
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The “Spanish Flu” pandemic of 1918, by some estimates [1], is
thought to have killed more individuals than any disease outbreak in
recorded human history. Thankfully, recent outbreaks of inﬂuenza have
not been as deadly, yet it remains a grave health hazard: In the United
States, according to the Centers for Disease Control and Prevention,
inﬂuenza and its complications are currently the leading cause of death
due to any infectious disease. Moreover, seasonal epidemics due to
antigenic drifts can more than double the mortality rates, while
antigenic shifts causingworld-wide pandemicsmay result in far greater
casualty levels, as was the case in 1918, 1957 and 1968.Avian inﬂuenza virus has been a cause of much concern [2]. In
December of 2003, the largest outbreak of avian inﬂuenza due to the
deadly H5N1 strain occurred in South East Asia. Although only a limited
number of peoplewere infected, it was reminiscent of the Spanish Flu of
1918, in that most deaths occurred in otherwise young, healthy
individuals. In this and other avian inﬂuenza outbreaks, bird culling
was immediately implemented, altogether leading to an estimated
slaughter of more than 100,000,000 birds, in an attempt to curb the
spread of avian inﬂuenza.
More recently, the emergence of a swine ﬂu pandemic fromMexico
City has been a causeofmuch concern [3]. As of April 25th2010, 477,593
reported cases have been conﬁrmed in 214 countries, resulting in
17,410 deaths. This H1N1 virus was clinically isolated in April of 2009
andwasdeﬁned as a phase six pandemic alert, themaximum level in the
WHO scale. The virus is an apparent reassortment of four endemic
strains of inﬂuenza: one from humans, one from birds, and two from
pigs [4], a fact that further exempliﬁes inﬂuenza's versatility.
Fig. 1. The structures of the anti-inﬂuenza A drugs amantadine (left) and rimantadine (middle). For clarity, only polar hydrogens are depicted. The space-ﬁlling representation of
amantadine is shown on the right. All structures are shown in their neutral form.
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inﬂuenza A, B and C. Type A inﬂuenza viruses are further divided into
subtypes based on the antigenic relationships in the surface
glycoproteins, hæmeagglutinin and neuraminidase. At present, 16
hæmeagglutinin subtypes have been recognized (H1–H16) and nine
neuraminidase subtypes (N1–N9). Each virus has one hæmeaggluti-
nin and one neuraminidase antigen, apparently in any combination.
All inﬂuenza A subtypes in themajority of possible combinations have
been isolated from avian species [8]. Still it is important to understand
that apart from the antigenic similarity on the surface glycoproteins,
the subtypes may contain differences in the rest of the genome. For
instance, not all the H1N1 (i.e. that have the same hæmeagglutinin
and neuraminidase antigens) have the same characters.
There are two different strategies for combating inﬂuenza: vaccina-
tion and chemotherapy. Vaccination effectiveness is limited due to the
antigenic drifts and shifts that the inﬂuenza virus undergoes from year
toyear. It is for this reason that chemotherapeutic agents are particularly
attractive. However, viral resistance to all classes of anti-inﬂuenza
agents, neuraminidase inhibitors and aminoadamantanes, is found [5].
Moreover, due to reasons that will be elaborated below, aminoada-
mantanes are effective only against inﬂuenza A strains, and are
completely ineffective against inﬂuenza B strains [6,7].1
In this review we will focus on the sequence variations by which
inﬂuenza develops resistance to amino-adamantyls, shown in Fig. 1.
We will begin by describing the major target of amino-adamantyls—
the M2 H+ channel. We will continue by discussing the sequence
variations that the M2 protein undertakes and the consequences on
its structure and channel activity. We will end by describing some
variations in the hæmeagglutinin protein that have been implicated in
resistance to amino-adamantyls.2. The M2 protein
The molecular target of the aminoadamantane drugs, amantadine
and rimantadine (the only members of the family approved for
prophylactic use) is the inﬂuenza A M2 H+ channel [9]. It is therefore
of no surprise, that M2 has been the focus of considerable attention.
The function ofM2was the last step to be elucidated in the life cycle of
the inﬂuenza virus [10]. Viral attachment and entry into the cell are
carried out through the activity of the major viral spike glycoprotein
hæmeagglutinin [11]. Membrane fusion and viral genome release occur
after hæmeagglutinin undergoes a pH-dependent irreversible conforma-
tional change in the acidic endosome. However, it was not clear at ﬁrst
why hæmeagglutinin did not change its conformation in the exocytic
pathway where the pH is sufﬁciently low to cause the conformational
change. The answer to this question came upon identifying the pH-1 Aminoadamantanes are ineffective against inﬂuenza C strains as well. However,
since inﬂuenza C virus does not pose a series health threat, all discussion henceforth
will be concerned solely with inﬂuenza A and B.dependent H+ channel activity of M2 [10], which negates the activity of
the Golgi H+ ATPase.
Perhaps more important is M2's role in the virus uncoating process,
after viral uptake by endocytosis. The passage of H+s from the acidic
environment of the endosomal lumen into the virus (through M2)
weakens the interactions between the matrix protein and the
ribonucleoprotein core, enabling the release of the viral genome into
the cytoplasm.
3. M2 structure
M2 was shown to be a homo-tetrameric membrane protein [12],
stabilizedbydisulﬁdebonds [13]. In addition, the transmembranedomain
of M2 exhibits ion channel activity and amantadine blockage that is
similar to that of the full-length M2 [14]. Taken together, it is clear that
tetramerization is initiated by the transmembrane domain and subse-
quently stabilized by cytoplasmic disulﬁde bonds.
Several techniques have produced structures for the M2 protein: X-
ray crystallography [15], solid-state NMR [16], solution NMR [17] and
our 1- and 2D-IR approach [18]. The reader is referred to a recent review
on this topic [19]. The X-ray study, in detergent micelles, was of a
peptide that encompasses the transmembrane domain of the protein
(residues Ser22–Leu46). Furthermore, two structures were obtained:
one at pH 7.3 (containing the I33M mutation) and another with
amantadine at pH 5.3 (containing the G34A mutation). Both structures
were shown to be highly similar to one another. The solid-state NMR
experimentally suggested model was also obtained for the same
transmembrane peptide, but this time in lipid bilayers [16]. Finally, a
solution NMR study of a slightly longer peptide (residues Ser23–Lys60)
with rimantadine was reported in detergent micelles, as well [17]. We
note that the peptide that was analyzed corresponded to residues
Arg18–Lys60, however, the N-terminal ﬁve residues were shown to be
disordered.
Remarkably, as seen in Fig. 2, there are substantial differences
between the various structures: The Cα-RMSD between the X-ray and
solid-state NMR structures is 4.01 Å, 4.04 Å between the X-ray and the
solution NMR and 4.63 Å between the two NMR structures. The tilt
angles of the helices in the solid-state NMR and X-ray structure are
similar (30–40°), in contrast to the 23° tilt observed by solution NMR.
Furthermore, while the helices in both solution and solid-state NMR
structures contact each other throughout, the X-ray structure
resembles a conical frustum, with the C-terminal parts splaying apart.
What is most intriguing about the different structures is the
location of the drug (see orange molecule in Fig. 2): In the X-ray
structure a single amantadine molecule was located in the pore,
implying a direct pore blocking model [15]. In contrast, in the solution
NMR structure four equivalent allosteric binding sites were found on
the exterior of the helical bundle facing the detergent micelle [17].
Moreover, this pocket is located far in the outer region, spanning
residues 41–45. The authors postulated that the closed form of the
Fig. 2. Structures of the M2 transmembrane domain obtained by three different techniques: X-ray crystallography [15], solid-state NMR [16] and solution NMR [17]. The Cα-RMSDs
between the different structures are indicated in the ﬁgure. His37 and Trp41 are shown in CPK representation, colored in blue or red, respectively. Amantadine or rimantadine are
shown in space-ﬁlling representation in gold.
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presumably enforces the energetically favorable closed state. Muta-
tions in the 27–31 spanning region destabilize the complex of the
channel and thus shift it to its open state once the pH drops. Finally,
the validity of each of these binding sites is a matter of considerable
debate [20–22].
4. M2 sequence variations
Whenever inﬂuenza viruses are confronted with amino-adaman-
tyls, such as amantadine or rimantadine (Fig. 1), they overcome the
resulting M2 channel inhibition by manipulating the sequence of M2
[9]. As seen in Fig. 3 the viral manipulation of theM2 gene is focused in
several sites with several variations at each site. A prediction of this
particular pattern of resistance mutations is yet to be found.
Since the M2 protein transmembrane segment adopts anα-helical
conformation in lipid bilayers [23–25] its residues exhibit a helical
periodicity of 3.6 amino acids per turn. This structural arrangement
places the amino acids that result in resistance to amino-adamantyls
(Fig. 3) in the channel pore and in close proximity to each other.Fig. 3. Sequences of the M2 transmembrane domain. Top panel: differences between the d
Singapore/Udorn, Weybridge, Rostock and swine ﬂu strains, respectively. The red residue in
Note that the transmembrane domain of Udorn strain is identical to that of Singapore. All of
indicate the different amantadine-resistant mutants and their respective “wild-type” strains
its amantadine-sensitive, wild-type parent strain, are marked in red. On the right is a helica
mutations hotspot positions, 27 and 31.Moreover, this dominant area is suspected as governing either the
activity of the channel and/or the binding of amino-adamantyls [15].
When investigating different types of the inﬂuenza viruses, one can
clearly notice the differences between the avian and human strains of
inﬂuenza as reported by Hay and colleagues [9]. Hay et al. reported that
avian strains suchas theA/Chicken/Germany/34 (H7N1Rostock) andA/
Chicken/Germany/27 (H7N7), (Rostock andWeybridge strains, respec-
tively) are inhibited by the application of amantadine prior and post
infection. Moreover the mutations that rendered the virus with
amantadine resistance at the M2 channel, focused mainly on positions
27, 30 and 34 in the case of the Weybridge strain. In the case of the
Rostock strain, the resistancemutations focused on position 27 only. On
the other hand, the human strain A/Singapore/1/57 (H2N2) was
inhibited when amantadine was implemented prior to infection only.
In addition, the resistance acquiringmutationsweremainly in positions
30 and 31. Another factworthmentioning is the variability ofmutations
per site, which is greater in positions 27, 30 as opposed to site 31 that
included one mutation only: S31N [9].
Another report that camemore than a decade later [26], showed the
same focus on sites 30 and 31, as the exclusive mutations sites causingifferent viral stains. Marked in purple, blue, green and brown are residues unique to
the swine ﬂu (S31N) indicates that it confreres resistance against aminoadamantanes.
the wild-type strains (except the swine ﬂu) are sensitive to amantadine. Bottom panels
. Sites in which differences occur between the mutant, amantadine-resistant strain and
l wheel diagram (3.6 amino acids per turn) of the Singapore strain indicating the two
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The difference in the mutation sites acquiring amino-adamantyl
resistance in avian versus human is important, since inﬂuenza A strains
are mainly transmitted by aquatic birds [27], and the differences may
link the possibility of a speciﬁc viral genome to cause the next human
pandemic.
Themutation site andaminoacid substitutionmaynotbe random, as
shown in a recent study investigating inﬂuenza strains that have high
potential to cause a pandemic [28]. In these instances the dominant
mutation inducing resistance is S31N (e.g.’ swine ﬂu as shown in Fig. 3).
This study also shows that the mutations occurred mainly after 1983
and were not found prior to that [28,29]. The noted drift toward the
S31Nmutation once human viruses were sequenced, was also noted at
Asian countries around the 2005 avian H5N1 outbreak [30], or even in a
more recent study [31]. Thus, an optional scenario is that the S31N
mutation, revealed in genomes other than genome B (human origin) is
tightly related to strong outbreaks of human inﬂuenza, or signals high
selective pressure of amino-adamantyls (high usage). Signs of S31N
mutations that were linked to major inﬂuenza outbreaks were also
reported by others, next to the last avian ﬂu outbreak that followed
[30,32–34]. Similarly the previous Swine ﬂu attack was followed by the
appearance of S31N resistant mutation [35,36].
Another scenario postulates that the appearance of the S31N
mutations could all be linked to the emergence of viruses from the
same linage, as presented for the A/H3N2 between the years 2004 and
2006 [35], or later in pigs [29]. Interestingly, a recent study from Japan
clearly showed that between the years 1999 and 2001, the H3N2 strains
gained higher tolerance (compared to H1N1 strains at the same years)
against amino-adamantyls [37]. In this instance the resistance was
achievedoncemorebymutating theM2serine 31 to asparagine (S31N).
In contrast, H1N1 assayed viruses that gained lower degree of amino-
adamantyl resistance, showed clear preference of the M2 valine 27 to
alanine (V27A) mutation. Other reports also marked the difference in
the twomutationsmentioned above. For instance, in the case ofWSN/33
(H1N1), both mutations could bring to amino-adamantyl resistance of
the inﬂuenza virus, but to a different extent [38]. In this assay, the
reported amantadine IC50s of viral plaques infecting MDBK cells, were
almost one order of magnitude higher in the case of V27A (WSN/33
(H1N1)) mutated M2 (2012 fold higher than wild-type), versus the
S31Nmutant (294 fold higher thanwild-type). Surprisingly, theweight
loss and mortality percentage were slightly higher in the case of the
S31N mutant.5. Mutations in M2 and their effect on activity and stability
If the scenario proposed above is true, then what is the cause for the
S31N low IC50 estimate? To answer this question one has to estimate
the structural basis of the twomutations. One of the striking differences
is of course the size alteration direction of the mutations (“mutation's
direction”). In the case of the S31N, the replacement is to a bigger amino
acid, and vice versa in the case of the V27A. If both sites are lining the
pore or facing inwards, then in the case of mutations following the
direction of the S31N mutation, the channel's pore size is most likely
reduced. The opposite occurs in the case of V27A,whereby the channel's
pore iswidened [39]. This observationmaybe the reason for the changes
in the H+ﬂuxes of the two mentioned mutated M2 ion channels, as
viewed in oocytes [10]. Indeed, the S31N mutation applied to the A/
Udorn/72- M2 ion channel, showed a decreased current and the V27A
showed an increased current of protons through the channel when
compared to the wild-type A/Udorn/72- M2 ion channel. A later study
calibrated channel activity with protein expression and found that the
decrease in conductivity of the S31N mutation was not as high [39].
Finally, this experiment was handled under neutral pH and therefore
most of the ion channels is in the closed state, though still leaky and
responding to the addition of amantadine [41].Another noted observation regarding the differences between the two
directions of themutations, is the activity of themutations. In neutral pH,
though theV27Amutation in theA/Udorn/72M2 ion channel renders the
virus amantadine resistant, the channel is still affectedby thedrug [10]. As
a consequence, the addition of 100 μM amantadine causes a decrease of
approximately 33% in the channel's activity. That is not the case of the
S31N mutated M2 ion channel. Speciﬁcally, this particular mutation
renders the virus amantadine resistance aswell, but under neutral pH it is
hardly affected by the drug [10,39].
Later work, explored the inﬂuence of amantadine on the very same
ion channels, in lower pH conditions [40]. This experiment under
conditions in which the channel is mostly in the open state [10,41],
showed one order of magnitude higher inﬂux of protons through both
mutated channels. Upon the addition of amantadine, the S31N
mutated M2 ion channel, showed a decrease in activity of approxi-
mately 30%, as opposed to lack of inhibition in the neutral pH. The
V27A mutated M2 ion channel showed only 20% decrease of activity
as opposed to 33% in neutral pH, as mentioned above [40]. When
focusing on the activity levels of the twomutated channels (S31N and
V27A), even after taking into account the M2 ion channel's different
expression levels, the V27A, mutated M2 ion channel has greater
activity in neutral and acidic pH conditions [10,40].
A possible explanation for these observations could be the
differences in the binding afﬁnities or the impact of the amino-
adamantyls on the different ion channels, when a different pH range
is used.When the pH is neutral (7.5),most of the ion channels are either
closed or allowonly a very low conduction of protons. Since the inﬂux of
protons through the S31N ion channel is lower than the V27A mutant
[10,40], due to possible narrowing of the pore [39], the addition of
amantadine could have little or no inﬂuence on the channel at all.When
the pH is lowered, the proton ﬂux is increased or the channel's pore is
wider and the inﬂuence of the amantadine block is much more
pronounced. This phenomenon of pH-dependent blocking by amanta-
dine (on the S31N mutated M2 channel) was observed in a later report
aswell [42]. In the case of theV27A, theprotonﬂux is greater (compared
to the S31N case) in any pH [10,40]. Thus, if the addition of amantadine
in neutral pH results in a notable (though not full) blocking effect on the
channel, when the pH is lowered, the ﬂux is higher and the channel's
pore is optionally wider than the optimum for an effective amantadine
block.
Another option could be the differences between the binding
afﬁnities of amino-adamantyls to the M2 channels in the different pH
values. It is also possible that the binding of drug to the S31N mutated
ion channel is low in high pH conditions, and is increased in low pH.
Accordingly, the V27Amutant could show the direct opposite direction
of binding afﬁnity as the pH drops. Nevertheless, it is important to
remember that different ion channels are affected differently by the
same mutation. A simple comparison of the G34E, A30P and S31N M2
mutations in the different inﬂuenza strains Rostock, Weybridge and
Udorn [40] or the L38F mutant in the Rostock and Udorn strains [22],
clariﬁes this point.
Taken together it is possible that resistance to amino-adamantyls
has an effect on the protein's function and structure. This ﬁnding is
similar to the effect of mutations on hæmeagglutinin, discussed below
in Section 6. Further examples of the resistance mutations are
correlated with a decrease in channel's activity, as shown for the A/
Udorn/72 (H3N2) M2 mutants: S31N [10], A30P and A30T [40]. It is
possible that these observations are responsible for the retarded
growth of some resistant viruses. Still as mentioned above, the same
mutation can have different impact on different M2 types.
Grambas et al. showed when investigating the A/chicken/Germany/
34 (H7N1 Rostock) M2 mutants: A30T, A30E, L26H and S31N, that the
growth of thesemutated viruses is retarded compared to Rostock wild-
type strain [43]. Other mutants such as I27T showed elevated activity
compared to the Rostockwild-type channel [43]. Moreover, the authors
stated that the impaired growth capacity of certain mutants in chick
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the presence and in the absence of amantadine. During passage in the
absence of the drug, mutants A30T and G34E readily reverted to the
wild-type, i.e. amantadine-sensitive phenotype. The S31N mutant
acquired a compensating mutation, I27T which, while retaining drug
resistance, conferred improved growth characteristics similar to those
of the single mutant I27T. Similarly, passage of A30T and S31Nmutants
in the presence of amantadine selected variants with the same
additional alteration, I27T, and phenotypic characteristics.
The observation of low stability due to impaired growth while
acquiring resistance, could explain the presence of sensitive viruses
remains, in patients that were treated with amantadine [44]. This
report showed that as long as amantadine treatment continued,
mutated resistant viruses were formed, yet the wild-type sensitive
form of virus was always present, presumably in small titers. Once the
amantadine treatment was stopped, the sensitive viruses over-
powered the mutated form in those patients.
One intriguing question that was further investigated was the link
between the inner radius of the pore and the proton conductance
ability of the M2 channel. We speculated once before [39] that the
mutation direction (from small residue to large one and vice versa)
could inﬂuence the channels inner pore radius. In order to link the
channel's diameter to its activity, we expressed the three different M2
ion channels in Escherichia coli using the pMal-p2x expression system
from New England Biolabs (Ipswich, MA) [45]. The expression level
that was controlled by the addition of Isopropyl-β-D-thio-galactoside
(IPTG), brought to a pronounced decrease in bacterial growth (as
observed by OD600).
As presented in Fig. 4, the inhibition was lower in the A/chicken/
Germany/34 (H7N1 Rostock) strain compared to the A/Singapore/1/57
(H2N2) M2 ion channel, and was lowest in the S31N mutated A/
Singapore/1/57 (H2N2). Since the ionconductance is proportional to the
inhibitionof growth (higher inﬂuxof protons=stronger inhibition),we
can learn that the ion conductance is the highest in the wild-type
Singapore strain, lower in the Rostock strain and lowest in the
Singapore-S31N mutant. The effect of mutation in the Singapore S31N
mutant versus the Singapore wild-type is most likely narrowing of the
pore [39]. It is also plain to see that the Rostock strain has the same size
direction as the Singapore S31N,when compared to the Singaporewild-
type. A comparison of amino acids 22–46 that were shown to
encompass the M2 transmembrane region [46] between the two
strains, reveals three amino acids that differ in the M2 transmembrane
region (see Fig. 3). The difference of asparagine 44 in Rostock versus
aspartate in Singapore has optionally a little size impact. In contrast,Fig. 4. Activities of different M2 channels, as measured by their effect upon the growth
retardation of the host bacteria. Speciﬁcally, higher growth rates of the host bacteria
indicate weaker channel since it does not have a deleterious effect [45].sites 27 and 28 contains isoleucines 27 and 28 in the Rostock strain
versus valines 27 and 28 in the Singapore strain [9], that has optionally
greater size difference, leading to a wider Singapore pore.
It is important to mention the differences between the different
ion channels tested by Grambas et al. [43]. The Rostock and Weybridge
M2 channels differ not only in their structure and sensitivity to point
mutations such as the G34E [43], but also in their activity and ion
ﬂux aswell. Chizhmakov et al., found that the RostockM2 ion channel has
5–8 times higher inﬂux of protons than the Weybridge strain [47]. The
authors also found that the activity mode of amantadine is slower than
predicted by a diffusion limited ligand binding model as did Wang et al.
[41]. These authors explained this observation by the possibility of an
equilibrium state between the opened and closed channels. Finally the
authors state that three mutations are necessary in order to convert
the Weybridge M2 to the Rostock strain activity level, while only one is
sufﬁcient to do the opposite.
6. Hæmeagglutinin sequence variations
In addition to the inﬂuence of amino-adamantyls on the M2 ion
channel's sequence, the presence of the drugs has an impact on the
hæmeagglutinin protein. As in the case of the amantadine resistance in
theM2protein, thehæmeagglutinin proteinwas found to contain various
mutations in the amantadine resistant viruses [48]. In some cases the
mutated hæmeagglutinin that arose by the growth in the presence of
amantadine, is sufﬁcient to provide amantadine tolerance [43,49,50]. The
amantadine stress has twodifferent levels of action, in lowconcentrations
(0.1–5 μM) and in high concentrations (N100 μM) [9]. Low concentration
of amantadine imposes a blockage of the M2 channel in the Trans Golgi
Network (TGN). This action results in the decrease of the pH in the TGN
that cannot be elevated by the M2 ion channels (since they are blocked).
When the pH decreases below a critical level, the hæmeagglutinin
proteins are shifted to the lowpH form that is responsible for the fusionof
membranes [51]. This conformation change is irreversible, and as a
consequence high levels of low pH form hæmeagglutinin reach the
plasmamembrane (as in the case of the Rostock strain)with concomitant
impaired release of virions [9,52].
The hæmeagglutinin transformation to its low pH form can take
place only after its subunit cleavage [53]. In regards to this fact, it is
important to mention that most inﬂuenza A hæmeagglutinins are not
cleaved intracellularly (as in the case of the Singapore andmany other
strains) and thus cannot shift to the low pH form in the Golgi [54]. The
second route leading to the same result is by the application of
amantadine at higher concentrations as mentioned above. This route
takes a non speciﬁc manner of inhibition [9,48]. The amantadine drug
acts as an amino weak base, in high concentrations (N0.1 mM). The
molecule has the ability of elevating the lysosomal pH by almost 2 pH
units. Amantadine is not the only amine capable of elevating the pH,
other amines can impact pH as well [55,56]. Taken together, the direct
impact of amantadine treatment is the elevation of resistant viruses
with point mutations at the hæmeagglutinin without additional
mutations in the M2 ion channel.
As mentioned above, the S31N mutation in various inﬂuenza M2
types causes impaired growth [43]. In viral infections such as the
Rostock strain, the S31N mutation can also bring about the presence of
high levels of low pH form of hæmeagglutinin in the cell plasma
membrane [43]. If the virus’ inoculum is passed again in the absence of
the drug, a compensatingmutation such as the I27T reduced the low pH
formhæmeagglutinin level to thewild-type level [43]. Interestingly, the
authors described the reduced activity of Rostock M2 mutations L26H,
A30T, S31N and G34E (A/chicken/Germany/34 (Rostock)). These
mutations caused a substantial increase in the expression of the low-
pH form of hæmeagglutinin. In addition, sequence changes were
observed during subsequent passage of these mutant viruses in the
presence or absence of amantadine: reversion to the wild-type form,
acquisition of a second suppressormutation inM2, or the appearance of
552 P. Astrahan, I.T. Arkin / Biochimica et Biophysica Acta 1808 (2011) 547–553a complementary mutation in hæmeagglutinin which increased its pH
stability [43]. In contrast, l27T and l27Smutations caused an increase in
M2 activity. Furthermore, in double mutants the l27T mutation
suppressed the attenuating effects of the A30T and S31N mutations on
M2 activity. Finally, in this study, the Rostock hæmeagglutinin
mutation hæmeagglutinin2-K58I (a mutation found to decrease viral
growth [49]) yielded a decreased pH in which high to low form pH
transformation occurred in the hæmeagglutinin. This drop in pH
regulates the stability of the hæmeagglutinin that was required by the
S31N-K58I doublemutant (that has an inhibitedM2ﬂux). Other reports
of mutations in the hæmeagglutinin that reduces the high to low pH
transformations of the protein are consistent with this study [48], such
as the Hemeagglutinin2-G23C mutation [50].
Most inﬂuenza viruses, Rostock strainbeingoneexception, are not as
sensitive to the Golgi inner pH. When comparing the hæmeagglutinin
resistant mutations in other strains (such as the Weybridge inﬂuenza
strain) to the Rostock strain, the transformation to the low pH form
occurs in higher pH values (the opposite) [48,49]. It is possible to
rationalize these observations, in that the strains such as Rostock are
exposed to the acidiﬁcation of the Golgi with no relief by the M2 ion
channel in the presence of amantadine. Thus the hæmeagglutinin has to
bemaintained in its high pH form in lower pH conditions, and yet retain
fusion capabilities in the late endosome stage. The opposite phenom-
enonmay occur in strains that are not as sensitive to the Golgi pH, since
in this case the problem is fusion in the late endosome stage with low
acidiﬁcation condition in the presence of amino-adamantyls. Thus their
hæmeagglutinin shifts to its low pH form in higher pH values.
As presented by Daniels et al. the hæmeagglutinin mutations in
different inﬂuenza strains (X-31 and Weybridge) are focused in
different parts of the protein (hæmeagglutinin1 or hæmeagglutinin2)
[47]. In this regard, different types of amino acid mutations are taking
place in each part: hæmeagglutinin1 mutations are directed towards
charged amino acids and hæmeagglutinin2 mutations are from acidic
amino acids to neutral ones. Also the amino terminal of the
hæmeagglutinin is the area which response to the pH alteration [48].
Finally, the role of hæmeagglutinin in the resistance against
amino-adamantyls seems to vary between the different strains. In few
cases such as the 2009 reported H3N2 inﬂuenza infected patients, the
viruses isolated from the patients included mainly M2 mutations.
Hæmeagglutinin mutations were hardly present and were only forced
out by in vitro passages [57]. In other types (H7N7) they are the only
cause of resistance [50]. The fusion pH also varies between the
different wild-type strains [43,48,49].
7. Mutation rate
It is reasonable to assume that there are different constrains (such as
crucial site's structure/function) dominating the mutation rates between
different proteins. Thus it is likely that some constrains in addition to the
above mentioned, rule the spread of a speciﬁc inﬂuenza type strain or
mutant, overmutations that take place in other viral proteins. This notion
can explain the results by Nobusawa and Sato [58]. This assay showed a
highermutation rate in the A types of inﬂuenza as opposed to the B types.
The authors also presented variations in the mutation rate between the
types A (H3N2 versus H1N1) and in the B types as well [58]. Thus it is
likely that some mutations are more wide spread in a speciﬁc type of
inﬂuenza, not due to evolutionary stress selection fromrandomoccurring
mutations, but rather from an indirect reason.
8. Concluding remarks
We have tried to discuss the various mutations that the inﬂuenza
virus undergoes during its evolution of resistance to amino-adamantyls.
The majority of mutations are in the M2 protein which is the prime
target of the drug, while some mutations are in the hæmeagglutinin
protein mostly due to the impact of amino-adamantyls on the pH. Theimpact of the resistance mutations on virus viability have been
discussed as well, since this has direct ramiﬁcations when designing
new channel blockers against M2.
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